Please provide your email address to receive an email when new articles are posted on . Researchers from Canada found placement of an arteriovenous fistula slowed decline in kidney function for ...

The study findings might indicate residual kidney function preservation in advanced CKD. Arteriovenous fistula (AVF) creation is associated with a slowing of kidney function decline in patients with ...

In a trial, an acellular tissue engineered vessel had superior functional patency for hemodialysis with acceptable safety compared with an arteriovenous fistula in high-risk patients. An acellular ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

Neither omega-3 fatty acids from fish nor aspirin prevented failure of arteriovenous fistulae (AVFs) in patients receiving hemodialysis, according to results of a new study published online January 3 ...

This requires durable access to a blood vessel site where the dialysis machine can remove and return blood. Such access is created when a surgeon attaches a vein to an artery in the patient. The ...

A simple reversal of the way a long-standing surgical procedure is performed to create an arteriovenous fistula for hemodialysis access significantly improves the fistula's function and longevity over ...

To undergo kidney dialysis, doctors must first surgically create an access route—an arteriovenous fistula—usually in an arm, a conduit that will accommodate hemodialysis treatments. It is a routine ...

Humacyte (NASDAQ:HUMA) outlined the unmet need in hemodialysis vascular access and highlighted data from its clinical program evaluating the company’s acellular tissue engineered vessel (ATEV) as an ...

Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it will host ...